The detrimental effects of kynurenine, a tryptophan metabolite, on human bone metabolism

Beom Jun Kim, Mark W Hamrick, Hyun Ju Yoo, Seung Hun Lee, Su Jung Kim, Jung Min Koh, Carlos M Isales

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Context: Studies in aged mice support a role for kynurenine, a tryptophan metabolite, in age-induced bone loss; however, the role of kynurenine in human bone metabolism is not well understood. Objective: To assess whether the kynurenine level in bone marrow (BM) aspirates, directly reflecting the bone microenvironment, is associated with osteoporosis-related phenotypes and bone biochemical markers. Design and Setting: A case-control study conducted in a clinical unit. Participants and Main Outcome Measures: BM samples were collected from 72 patients at the time of hip surgery for either fragility hip fracture (HF) (n = 27) or for other causes (n = 45). In these samples, kynurenine was measured by liquid chromatography-tandem mass spectrometry, and the levels of tartrate-resistant acid phosphatase 5b (TRAP5b), bone-specific alkaline phosphatase (BSALP), receptor activator of nuclear factor-kB ligand (RANKL), and osteoprotegerin (OPG) were measured by immunoassay. Results: Age was positively correlated with BM kynurenine level. After adjustment for confounders, subjects with fragility HF had a 39.7% higher BM kynurenine level than those without, and the OR per SD increment in BM kynurenine level for fragility HF was 3.80. The BM kynurenine level was inversely associated with bone mass at the total femur. Higher kynurenine concentrations were significantly associated with higher TRAP-5b and RANKL levels, but not with BSALP and OPG levels, in BM plasma. Conclusion: These results suggest that increased kynurenine levels during aging may contribute to the bone fragility seen in the elderly through increased bone resorption, with a resultant imbalance in bone remodeling.

Original languageEnglish (US)
Pages (from-to)2334-2342
Number of pages9
JournalJournal of Clinical Endocrinology and Metabolism
Volume104
Issue number6
DOIs
StatePublished - Jun 1 2019

Fingerprint

Kynurenine
Metabolites
Metabolism
Tryptophan
Bone
Bone and Bones
Bone Marrow
Hip Fractures
Cytoplasmic and Nuclear Receptors
Alkaline Phosphatase
RANK Ligand
Osteoprotegerin
Bone Remodeling
Bone Resorption
Tandem Mass Spectrometry
Immunoassay
Liquid Chromatography
Femur
Osteoporosis
Case-Control Studies

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Endocrinology
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

The detrimental effects of kynurenine, a tryptophan metabolite, on human bone metabolism. / Kim, Beom Jun; Hamrick, Mark W; Yoo, Hyun Ju; Lee, Seung Hun; Kim, Su Jung; Koh, Jung Min; Isales, Carlos M.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 104, No. 6, 01.06.2019, p. 2334-2342.

Research output: Contribution to journalArticle

Kim, Beom Jun ; Hamrick, Mark W ; Yoo, Hyun Ju ; Lee, Seung Hun ; Kim, Su Jung ; Koh, Jung Min ; Isales, Carlos M. / The detrimental effects of kynurenine, a tryptophan metabolite, on human bone metabolism. In: Journal of Clinical Endocrinology and Metabolism. 2019 ; Vol. 104, No. 6. pp. 2334-2342.
@article{850406bb99404313a6c850cb1a353d6b,
title = "The detrimental effects of kynurenine, a tryptophan metabolite, on human bone metabolism",
abstract = "Context: Studies in aged mice support a role for kynurenine, a tryptophan metabolite, in age-induced bone loss; however, the role of kynurenine in human bone metabolism is not well understood. Objective: To assess whether the kynurenine level in bone marrow (BM) aspirates, directly reflecting the bone microenvironment, is associated with osteoporosis-related phenotypes and bone biochemical markers. Design and Setting: A case-control study conducted in a clinical unit. Participants and Main Outcome Measures: BM samples were collected from 72 patients at the time of hip surgery for either fragility hip fracture (HF) (n = 27) or for other causes (n = 45). In these samples, kynurenine was measured by liquid chromatography-tandem mass spectrometry, and the levels of tartrate-resistant acid phosphatase 5b (TRAP5b), bone-specific alkaline phosphatase (BSALP), receptor activator of nuclear factor-kB ligand (RANKL), and osteoprotegerin (OPG) were measured by immunoassay. Results: Age was positively correlated with BM kynurenine level. After adjustment for confounders, subjects with fragility HF had a 39.7{\%} higher BM kynurenine level than those without, and the OR per SD increment in BM kynurenine level for fragility HF was 3.80. The BM kynurenine level was inversely associated with bone mass at the total femur. Higher kynurenine concentrations were significantly associated with higher TRAP-5b and RANKL levels, but not with BSALP and OPG levels, in BM plasma. Conclusion: These results suggest that increased kynurenine levels during aging may contribute to the bone fragility seen in the elderly through increased bone resorption, with a resultant imbalance in bone remodeling.",
author = "Kim, {Beom Jun} and Hamrick, {Mark W} and Yoo, {Hyun Ju} and Lee, {Seung Hun} and Kim, {Su Jung} and Koh, {Jung Min} and Isales, {Carlos M}",
year = "2019",
month = "6",
day = "1",
doi = "10.1210/jc.2018-02481",
language = "English (US)",
volume = "104",
pages = "2334--2342",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "6",

}

TY - JOUR

T1 - The detrimental effects of kynurenine, a tryptophan metabolite, on human bone metabolism

AU - Kim, Beom Jun

AU - Hamrick, Mark W

AU - Yoo, Hyun Ju

AU - Lee, Seung Hun

AU - Kim, Su Jung

AU - Koh, Jung Min

AU - Isales, Carlos M

PY - 2019/6/1

Y1 - 2019/6/1

N2 - Context: Studies in aged mice support a role for kynurenine, a tryptophan metabolite, in age-induced bone loss; however, the role of kynurenine in human bone metabolism is not well understood. Objective: To assess whether the kynurenine level in bone marrow (BM) aspirates, directly reflecting the bone microenvironment, is associated with osteoporosis-related phenotypes and bone biochemical markers. Design and Setting: A case-control study conducted in a clinical unit. Participants and Main Outcome Measures: BM samples were collected from 72 patients at the time of hip surgery for either fragility hip fracture (HF) (n = 27) or for other causes (n = 45). In these samples, kynurenine was measured by liquid chromatography-tandem mass spectrometry, and the levels of tartrate-resistant acid phosphatase 5b (TRAP5b), bone-specific alkaline phosphatase (BSALP), receptor activator of nuclear factor-kB ligand (RANKL), and osteoprotegerin (OPG) were measured by immunoassay. Results: Age was positively correlated with BM kynurenine level. After adjustment for confounders, subjects with fragility HF had a 39.7% higher BM kynurenine level than those without, and the OR per SD increment in BM kynurenine level for fragility HF was 3.80. The BM kynurenine level was inversely associated with bone mass at the total femur. Higher kynurenine concentrations were significantly associated with higher TRAP-5b and RANKL levels, but not with BSALP and OPG levels, in BM plasma. Conclusion: These results suggest that increased kynurenine levels during aging may contribute to the bone fragility seen in the elderly through increased bone resorption, with a resultant imbalance in bone remodeling.

AB - Context: Studies in aged mice support a role for kynurenine, a tryptophan metabolite, in age-induced bone loss; however, the role of kynurenine in human bone metabolism is not well understood. Objective: To assess whether the kynurenine level in bone marrow (BM) aspirates, directly reflecting the bone microenvironment, is associated with osteoporosis-related phenotypes and bone biochemical markers. Design and Setting: A case-control study conducted in a clinical unit. Participants and Main Outcome Measures: BM samples were collected from 72 patients at the time of hip surgery for either fragility hip fracture (HF) (n = 27) or for other causes (n = 45). In these samples, kynurenine was measured by liquid chromatography-tandem mass spectrometry, and the levels of tartrate-resistant acid phosphatase 5b (TRAP5b), bone-specific alkaline phosphatase (BSALP), receptor activator of nuclear factor-kB ligand (RANKL), and osteoprotegerin (OPG) were measured by immunoassay. Results: Age was positively correlated with BM kynurenine level. After adjustment for confounders, subjects with fragility HF had a 39.7% higher BM kynurenine level than those without, and the OR per SD increment in BM kynurenine level for fragility HF was 3.80. The BM kynurenine level was inversely associated with bone mass at the total femur. Higher kynurenine concentrations were significantly associated with higher TRAP-5b and RANKL levels, but not with BSALP and OPG levels, in BM plasma. Conclusion: These results suggest that increased kynurenine levels during aging may contribute to the bone fragility seen in the elderly through increased bone resorption, with a resultant imbalance in bone remodeling.

UR - http://www.scopus.com/inward/record.url?scp=85065559761&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065559761&partnerID=8YFLogxK

U2 - 10.1210/jc.2018-02481

DO - 10.1210/jc.2018-02481

M3 - Article

C2 - 30715395

AN - SCOPUS:85065559761

VL - 104

SP - 2334

EP - 2342

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 6

ER -